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Abstract: Medication adherence refers to whether individuals take their medications as 
prescribed by a healthcare specialist. Medication adherence is often understated; 
however, it is evident as a key element in optimizing care in the healthcare continuum. 
Epidemiological studies indicate that non-adherence of medications causes 125,000 
deaths annually and accounts for 10% to 25% of hospital and nursing home admissions in 
the U.S. Medication adherence is an integral part of the medical enterprise. Healthcare 
professionals should mollify medication non-adherence because non-adherent behavior is 
a preventive and expensive issue in the enterprise. Nevertheless, the understanding 
behind medication adherence is complex and individual. Adherence can be divided into 
dimensions that reflect this behavior. In this study, we assess specific determinants within 
these dimensions; adverse drug reactions and self-monitoring of blood pressure, and 
health professional involvement. Examining these determinants effect on medication 
adherence we found no significant difference in medication adherence. An improved 
understanding is vital to resolve the quandary behind medication-taking behavior and 
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Statement of the Problem 
125,000 Americans die annually due to poor medication adherence, and those numbers 
are rising (McCarthy, 1998).  New England Healthcare Institute (NEHI) estimates that 
potential savings from adherence and related disease management could be 290 billion 
annually 13% of health spending (NEHI Research Brief, 2009).  Medication adherence is 
becoming a burgeoning crisis in the United States as populations increase and 
pharmacotherapy becomes more prevalent (Brown & Bussell, 2011). Medication is a 
vital measure of the medical enterprise. Healthcare professionals should mollify 
medication non-adherence because non-adherent behavior is a preventive and expensive 
issue in the enterprise. If these troubles persist, this could lead to an increase of economic 
burden in the United States Healthcare System.  
Medication adherence 
The World Health Organization (WHO) defines medication adherence to long-term 
therapy as “the extent which a person’s behavior-taking medication...”. Adherence, is not 
solely limited to adherence to medications but to other treatments (e.g. diet, exercise, lab 
testing, devices) Adherence, compliance, and concordance are terms used 
interchangeably. The connotations of these terms are rather different. The terms 
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adherence is preferably used to describe this behavior. Adherence presumes the patient’s 
agreement with the recommendations (Brown & Bussell, 2011). The term compliance 
implies patient passivity. Patients are not coerced to under treatment given. Despite the 
physician’s professional judgement, the informed individual has the right to accept or 
decline treatment. Steiner and Earnest, professors at Colorado Health Sciences Center, 
argue both terms are controversial in describing medication-taking behavior because the” 
exaggerate the physician’s control over the process of taking medications.” (Steiner & 
Earnest, 2000).  The terms to describe the complex issues surrounding medication taking 
for chronic illnesses cannot be consolidated into one word. The defining this complexity 
will aid in avoiding assigning blame exclusively to patient and physicians and assist in 
identifying effective solution (Brown & Bussell, 2011). 
Purpose of the Study 
The purpose of the study is to gain a better understanding of medication taking behavior 
by assessing the elemental proclivity. Medication adherence is multidimensional. The 
impact of adherence is spread among several dimensions; the physician, the health care 
system, the condition, the treatment, and the patient (World Health Organization 
Incorporated, 2003). The study will investigate these dimensions by evaluating subjects 
about condition-related, therapy-related, and physician related determinants that are 
derived from medication adherence. Subjects will be asked a series of questions 
concerning their medication taking performance parallel to the present of adverse drug 
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reactions, blood pressure monitoring methods, and their encounters with specialist 
involving their healthcare. Understanding and assessing adherence is essential in treating 
chronic conditions to achieve optimal health outcomes for patients participating in long-
term therapies. 
H1: Individuals who experience ADRs and have consulted with a healthcare professional 
(physician or pharmacist) will have no difference in adherences rates than individuals 
who did not consult with a healthcare professional. 
H2: Individuals prescribed medications who possess health coverage will have no 
difference in adherence rates than those who do not possess health coverage. 
H3: Individuals prescribed medication who experience adverse drug reactions (ADR) 
have a no difference in adherence rate with individuals who do not experience ADRs. 
H4: Chronic disease patients who use medical monitoring devices that and measure vitals 
(blood sugar, blood pressure, etc.) for their illness have no difference in adherence rates 
to their prescribed drugs than those who do not use monitoring devices. 
Significance of the Research 
The implications of poor medication adherence are costly but can be prevented in 
the healthcare in America. Poor medication adherence poses a threat to two prevalent 
debatable subjects among a variety of stakeholders such as; key experts from consumers, 
and health providers in the medical enterprise, the growing economic burden and equal 
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quality of care for all patients (Bosworth, et al., 2007). The importance of this research 
will contribute to the general understanding of medication taking behavior. Adherence 
has been marginalized by the public because of its apparent lack of severity and 
seriousness in public health in America.  Further comprehension with the behavior can be 
accomplished by investigating certain determinants that effect of medication adherence 
rates among patients. The study focuses solely on these determinants: adverse drug 
reactions, medical professional involvement, and blood pressure monitoring induced by 
self-efficacy. Health care professionals can utilize this information to help optimize drug 
regimens and lower cost for patients. 
Delimitations 
This study will not reflect medication adherence in the general population of Oklahoma. 
The study will not have excluded participants. The study will not have a larger sample 
size to reflect the general population. The study will not be focused on participants who 
have solely have chronic illness such as patients with hypertension (high blood pressure) 
and hyperglycemia (high blood sugar). This is due to limited access, time constraints, and 
resources to collect data from a wide-range setting. 
Limitations 
The study was a correctional cross-sectional study, limited to patients who receive care 
from an independent, family owned retail pharmacy. The study is limited to a three-day 
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data collection period due to time constraints and limited resources. All participants must 
be currently taking prescribed medication from a licensed healthcare professional and are 
required to be 18 years of age or older. These criteria remain to conduct the study in an 
ethical and functional manner. Several limitations of this study must be acknowledged. 
First, this study will be based its findings on the self-report survey, meaning that 
information from participants is subject to recall bias and socially normative answers. 
This method of collecting data from participants is a valid and reliable self-report 
instrument because they provide convenience and frugality with use in a clinical setting. 
The study was a correlational evaluation and thus does not suggest causality.  Secondly, 
the study is limited in only displaying relationships between variables and the extent of 
those links (Brink & Wood, 2012). Finally, the study may have a small sample size 
(n=35), and participants were relatively homogenous, some influencing factors may not 
have been detected.  Thus, medication adherence, self-efficacy, and white-coat adherence 
may be forecasting factors for managing chronic illnesses, for example, self-monitoring 






MEDICATION ADHERENCE  
The Scope of the Problem 
Medications, from antibiotics to painkillers, have forever transformed our lives. Most 
research is centered on developing an exceptional benefit-to-risk profile for new drugs 
and not the health-related behaviors that extend beyond taking prescribed 
pharmaceuticals. Pharmaceutical therapy is one of the most common therapies practiced 
in medicine. Nearly seventy percent of Americans in the United States have taking at 
least one prescriptions drug in their lifetime (Mayo Clinic, 2013). Despite the benefits 
and effectiveness of prescription drugs, patients fail to take their medication as prescribed 
by the physician. As a result, patients suffer from the implications of poor adherence. The 
Center of Disease Control and Prevention (CDC) holds that Americans die annually due 
to poor medication non-adherence, approximately 125,000, and those numbers are rising 
with increasing use of pharmacotherapy (McCarthy, 1998; Centers for Disease of Control 
and Prevention, 2010).  New England Healthcare Institute (NEHI) advocate that potential 
savings from adherence and related disease management could be 290 billion annually, 
which is approximately thirteen percent of healthcare spending in the U.S. (NEHI 
Research Brief, 2009).  Medication adherence is a growing crisis, both economically and 
industrially, in the United States. Reducing barriers between adherence and patients can 
lower economic burden and increase optimal health outcomes for patients in the U.S.. We 
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must understand that as populations increase, illnesses rise, and growing use of 
pharmaceuticals makes medication adherence for patients and prescribers more pertinent 
and vital to the future of medicine (Brown & Bussell, 2011; Centers for Disease of 
Control and Prevention, 2010). 
The Theory Behind Adherence 
Medication-taking behavior has been attempted to be deciphered using multiple 
behavioral models. The multifactorial nature of the behavior makes adherence difficult to 
approach with a single intervention. There are more than 200 variables that correlate to 
medication adherence (World Health Organization Incorporated, 2003). These variables 
have been categorized into three categories the patient (beliefs, expectancies about health 
and treatment), patient’s disease (chronicity, medication taken, complicating factors), and 
patient’s relationship to the healthcare provider (Brawley & Culos-Reed, 2000). 
Nevertheless, self-monitoring perspectives, behavior capacity, and reinforcement 
concepts have been considered of central importance to understanding medication taking 
behavior (World Health Organization Incorporated, 2003).  Theoretical models such as 
health belief model, protection motivation theory, the theory of reasoned/planned 
behavior are composed of key concept that has been defined as facts of the higher-order 
social cognitive theory constructs self-efficacy and outcomes expectations.  
Medication adherence aligns profoundly with the construct of self-efficacy in the social 
cognitive theory because the theory encompasses the cognitive process behind adherence. 
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The Social Cognitive Theory (SCT) was proposed by a Standford University 
psychologist, Albert Bandura, in the 1980s. According to his theory, an individual’s 
belief that one can adhere to taking medication as prescribed would be interpreted as self-
efficacy. This element of self-efficacy in SCT stands as a fundamental construct and 
mediator that influences behavior. The construct of self-efficacy elucidates the 
complexities of medication-taking behavior.  
The basic principle behind self-efficacy is the higher the self-efficacy, the more the 
individual will believe they are capable of completing a task. Thus, the lower the self-
efficacy, the less the individual will believe they are capable of completing a task. 
Self -efficacy holds a different denotation opposed to other homogenous terms, such as 
self-esteem and self-concept. Self- esteem and self-concept deal with a general concept 
about topics, whereas self-efficacy is defined as the attitude towards specific task in a 
particular context.  
Self-efficacy holds four determining factors (See Fig. 1). These factors are performance 
outcomes (or outcomes expectations), verbal persuasion (social reactions), vicarious 
experiences, and physiological feedback. Performance outcomes are experiences that can 
influence the ability of an individual to perform a given task. The experiences can be 
interpreted as positive or negative. These experiences influence an individual’s ability to 
complete a specific task. For example, and individual taking isotretinoin (acme 
medication) may experience side effects, such as cheilitis (dry lips), and abstain from 
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taking their medications. However, an individual may also continue therapy as acme 
heals and scars disappear. Verbal persuasion influences self-efficacy through oral 
encouragement and discouragement pertaining to the individual’s performance.  
Coaching is a common form of verbal persuasion. Physiological feedback is described as 
sensations from the individual's body that add to their experience. How individuals 
perceive this emotional arousal influences their beliefs of efficacy. Lastly, people develop 
high or low self-efficacy vicariously through another person’s performance. For instance, 
patients may observe a coworker in distress when taking an antibiotic and as a result feel 
they are just susceptible to the agony. All four contributors to the capacity of self-efficacy 
an individual may possess, depending on the magnitude of the four determinants.  
 




Albert Bandura’s theoretical framework for self-efficacy explains the cognitive process 
behind medication adherence (See Fig. 2 & 3). According to Bandura’s theory, a patients’ 
belief that one can adhere to taking medication as prescribed (self-efficacy). This remains 
a fundamental concept and mediator that influence other ideas that affect adherence. A 
patient’s self-efficacy influences one’s expectation of outcomes from adhering to the 
Figure 3- Albert Bandura's Theoretical Model of Self-Efficacy amended for medication adherence (above) 




prescribed medication (outcome expectations), which then influences adherence. For 
example, with self-efficacy, patients expect adherence to medication to improve one’s 
medical condition (physical outcomes, physiological feedback) expects to be supported 
by society (social reactions; health care professional approval), and expects adherence to 
medication to be self-satisfying (self-evaluative reactions). Outcome executions can also 
be seen a mediating role in adherence to prescribed medication, because, with these 
positive expectations, patients will likely adhere to prescribed medication. Patients also 
consider their environment (sociostructurally factors): a confident belief in one’s 
capability to adhere (self-efficacy) enables him to identify facilitators of adherence in 
one’s environment and to overcome various impediments ((ADRs) Adverse Drug 
Reactions). SCT proposes that positive perceptions of self-efficacy, outcome 
expectations, and sociostructurally factors (verbal persuasion) influence short-term goal 
setting and positive attitudes are reflected in higher attainable goals towards adherence.  
Albert Bandura’s SCT, concerning self-efficacy, traces out the cognitive process behind 
medication adherence and how the determinants under investigation may influence the 
behavior. His model for self-efficacy outlines direct relationships between medication 
adherence and impediments such as adverse drugs reactions. Furthermore, the framework 
shows how their beliefs can polarize outcome expectations, vicarious experiences, and 
physiological feedback about medication prescribed and influence medication adherence. 
The study aims to understand the dimensions of Bandura’s determinants for self-efficacy 
and their applicability to medication adherence concerning essential barriers such as cost, 
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clinician-patient relationships, self-monitoring conditions, and adverse drug reactions, 
along with evaluating the associations between the barriers above and adherence. 
The Clinician-Patient Relationship 
Adherence with patients has been correlated with the quality of the relationship that 
patient have with their healthcare providers, particularly physicians and pharmacist 
(Brown & Bussell, 2011).  The clinician-patient relationship is central to the practice of 
healthcare. The clinician-patient relationship is described as personal awareness of 
patients' unique personality structures (Fortin, Dwamena, Frankel, & Smith, 2012). It 
plays a vital role in the delivery of high-quality healthcare, both in the diagnosis and 
treatment of a disease or condition. The clinician-patient relationship shapes the 
foundations of contemporary medical ethics. (Goold & Lipkin, 1999) Susan Goold and 
Mack Lipkin, both medical professionals, have reviewed and studied the distribution of 
limited healthcare resources, exclusively from the views of patients and the public. Goold 
and Lipkin advocate that the clinician-patient relationship requires transparency and 
reciprocity between both parties.  The medical care enterprise is an unfamiliar and 
multifaceted course for patients. Albert Bandura’s Theory of Self-Efficacy postulates that 
patients can be influenced by the environment and subjective facilitators (e.g., friend). 
These factors may affect adherence and draw parallels between medication-taking 
behavior and quality relationships with physicians and other healthcare providers It is 
fundamental to understand the patient cognitive process throughout this healthcare 
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system. Healthcare providers should improve adherence by increasing positive verbal 
encouragement within communication. Positive verbal encouragement from providers 
can help patients navigate through the healthcare system with confidence and optimize 
their health outcomes (Raynor, et, 2007).   
A cross-sectional study was done by Dr. Worth, and Dr. Pathman in Primary Medication 
Adherence addresses a correlation between medication adherence and communication 
among healthcare professionals. Wroth and Pathman studied the adherence among rural 
populations using a telephone survey (Wroth & Pathman, 2006 ). The results revealed 
that 3926 respondents that have received care the previous year, 894 (21.6%) reported 
that they had delayed or did not fill a prescription over a period (Wroth & Pathman, 2006 
). Researchers observed delaying or not filling prescriptions was more common among a 
particular group of people. These people were 65 years or younger, of African descent, 
reported incomes less than 25,000, and reported fair or poor health. Researcher point 
outpatients had issues due to a lack of confidence in their provider’s ability to help them 
(Wroth & Pathman, 2006 ). Patients also described having a lack of satisfaction with 
concern shown them by physicians. Patients finally admitted to a lack of satisfaction with 
how welcome and comfortable they are made to feel by office staff (Wroth & Pathman, 
2006 ). The data reveals the significance of physician-patient communication on 
medication-taking behavior and patient satisfaction (Wroth & Pathman, 2006 ).  
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Trends in medication adherence and patient-physician communication have been 
associated with the behavior phenomena, white coat adherence. White coat adherence is 
not salubrious for long-term therapies but shows a connection between healthcare 
professional’s authoritarian symbol and medication adherence (Modi, Ingerski, Rausch, 
Glauser, & Drotar, 2013).  Investigators identified the clinical visits as anchoring points 
for patients (Modi, Ingerski, Rausch, Glauser, & Drotar, 2013). However, this type of 
medication-taking behavior has inconsistencies. Researchers some intervals between 
clinic visits displayed increases adherence before and after visitations (Modi, Ingerski, 
Rausch, Glauser, & Drotar, 2013).  This white coat adherence phenomenon discloses the 
magnitude of impact healthcare providers have on their patients. Thus, parallels can be 
drawn between adherence and patient-physician communication. 
By what means patients value clinician-patient connection is vital to generating 
adherence to treatments. Thus, clinicians should allow patients to engage in the decision-
making process regarding treatment. Understanding the presence and quality of the 
clinician-patient relationship from the patient’s perspective is an auxiliary emphasis of 
the study. The study hypothesizes that patients who regularly encounter health care 
professionals (physician, pharmacist, radiologist, etc.) have higher medication adherence 
rates. The thesis will evaluate this clinician-patient relationship revealing the correlation 
among adherence rates. Communication between physicians and patient, along with the 
patient’s knowledge of their condition and the selected treatment may provide the 




In the study of adherence, the auxiliary emphasis is placed on the superficial determinants 
of medication adherence, such as cost-sharing. Cost sharing is defined as the share of the 
costs covered by an insurance policy and the beneficiary. The term includes deductibles, 
coinsurance rates, and copayments. This does not include premiums, balance billing 
amounts for non-network providers, or the cost of non-covered services (HealthCare.gov, 
2017). According to the annual report on health insurance coverage from the Census 
Bureau, the uninsured rate dropped to 9.1 percent down from 10.4 in 2014. The number 
of American’s without insurance also dropped, to 29 million from 33 million the year 
before (Rovner, 2016). Associations between adherence and different sources of health 
coverage will be investigated in the study. Also, the study will assess the association 
between adherence and cost-sharing to get a better understanding of the relationship 
between patient cost-sharing and medication-taking behavior. Studies concerning cost-
sharing, health insurance, and adherence allow to investigators to understand how these 
determinants influence behavior.  In a meta-analysis, a wide variety of interventions 
types, study populations, and sample sizes was summarizing to provide an estimate of the 
relationship between changes in cost-sharing and medication-taking behavior. For each 
dollar increase in patient copays, adherence (as measured by the studies) would be 
expected to decrease by 0.4 percent (Eaddy, Cook, O'Day, Burch, & Cantrell, 2012).  For 
example, if a patient has a 20-dollar copay for a prescribed medication, adherence would 
expect to decrease by 6.8 percent overall. Albert Bandura’s theory corroborates with 
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findings in the meta-analysis. Albert Bandura’s theory does show that behavior can be 
influence by physical factors in the environment such as copayments. The “vicarious 
experiences” construct is logically applicable in these findings on cost sharing and 
adherence. For example, high copayments can be perceived as a burden. Neophyte 
patients may interpret this in the same manner, given the patient possess homogenous 
proclivities in behavior. with regards to this evidence, postulate individuals with health 
insurance will have no difference in adherences rates than individuals who possess 
coverage. 
Adverse Drugs Reactions  
Adverse drug reactions (ADR) are among one unavertable reason patients modify their 
drug regime and discontinue their therapy. Adverse drug reaction (ADR, or adverse drug 
effect) is a comprehensive term referring to unwanted, uncomfortable, or dangerous 
effects that a drug may have (Marsh, 2016).  Adverse drug reactions can be considered a 
form of toxicity; toxicity is most commonly applied to effects of over-ingestion 
(accidental or intentional) or to elevated blood levels or enhanced drug effects that occur 
during appropriate use (e.g., when medication metabolism is temporally inhibited by a 
disorder or another drug). The term side effect is imprecise. Often the term is used to refer 
to a drug’s unintended effects that occur within the therapeutic range (Marsh, 2016).   
ADRs have the potential to become severe and unpredictable. There are three types 
adverse drug reactions allergic dose-dependent, and idiosyncratic adverse drug reactions. 
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Most adverse drug reactions are dose-related meaning these drugs possess a narrow 
therapeutic index, such amiodarone (an antiarrhythmic agent). Other ADRs are allergic or 
idiosyncratic. Allergic ADRs are not dose-related and require prior exposure. Allergies 
develop when drugs act as an allergen or antigen. After patients are sensitized, 
subsequent exposure to drug produces one of several different types of allergic reactions. 
Clinical history and appropriate test can sometimes help predict allergic ADRs (Marsh, 
2016). Dose-related ADRs are commonly predictable; ADRS unrelated to dose are 
unpredictable. All medications carry the potential risk of adverse reactions. In the US, 3 
to 7 percent of all hospitalizations are due to adverse drug reactions. ADRs occur during 
10 to 20% of hospitalizations; about 10 to 20% of these ADRs are severe (Marsh, 2016). 
Adverse drug reactions from medications can deter a patient from continuing their 
treatment or make modifications to subside the side effects (Farlex Partner Medical 
Dictionary, 2012). 
A link between medication adherence and adverse drug reactions for an antiretroviral 
medication was studied among HIV patients. The most common adverse effects of the 
Highly Active Antiretroviral Therapy (HAART) are gastrointestinal (O'Brien, Clark, 
Besch, Myers, & Kissinger, 2003).  Anorexia, nausea, vomiting, and diarrhea are 
common side effects experienced by patients taking this medication. These adverse drug 
reactions have consistently lead to decreased adherence. HIV patients receiving HAART 
therapy engendered a level of adherence that was less than 80 percent of 46 percent of the 
sample population, 80-95 percent less adherent among 28 percent of the population and 
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95 percent less adherent among 26 percent of the population (Rajesh, Sudha, Varma, & 
Sonika, 2012). The non-adherence may result from patients self-adjusting their regimen 
due to adverse side effects and the toxicity of the drug or discontinued their therapy. With 
HAART another side effect is lipodystrophy, Kasper and colleges found that 37% of their 
respondents stopped their treatment or changed medication because they developed 
lipodystrophy (Rajesh, Sudha, Varma, & Sonika, 2012). Even of those who were 
adherent in the study, 57 percent seriously considered discontinuations of their therapy. 
Harsh adverse effects can steer patients to sporadic adherence and discontinuation of 
therapy.  
In a recent study, 876 individuals diagnosed with schizophrenia, displayed what could be 
a possible pattern of non-adherence among patients experiencing side effects due to 
excessive weight gain and cognitive impairment (DiBonaventura, Gabriel, Dupclay, 
Gupta, & Kim, 2012).  The majority of the schizophrenic patients experienced at least 
one side effect, 86.19 percent. Nearly, 42.5 percent Patients reported a complete 
adherence to their medications. Nearly a quarter (22.3%) of these participants reported 
discontinuing their treatment because these patients “felt worse” than before, only after 
taking the prescribed medication.  The side effect data is clustered into a single model. In 
those clusters, extrapyramidal symptoms (EPS)/agitation (OR)= 0.57, P = 0.0007, 
sedation/cognition (OR = 0.70, P = 0.033), prolactin/endocrine (OR = 0.69, P = 0.0342), 
and metabolic side effects (OR = 0.64, p= 0.0079), all displayed a correlation between 
adherence rates and side effects. The data revealed lower adherences significantly 
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reduced with side effects (DiBonaventura, Gabriel, Dupclay, Gupta, & Kim, 2012). In the 
study reported that patients with complete adherence to their medication were 
significantly less likely to report a hospitalization for a mental health reason (OR = 0.51, 
p = 0.0006), hospitalization for a non-mental health reason (OR = 0.43, p = 0.0002), and 
an emergency room visit for a mental health reason (OR = 0.60, p = 0.008). Among 
patients with schizophrenia (DiBonaventura, Gabriel, Dupclay, Gupta, & Kim, 2012). 
Medication side effects are highly prevalent and stand as significantly associated with 
medication adherence. Non-adherence was significantly associated with increased 
healthcare resource use.  Identifying medication-induced side effects, using preventive 
strategies to effectively manage these side effects will increase medication adherence, 
reduced healthcare resources, and optimize health care outcomes. 
Most patients are not well-informed about the ADRs medications hold. One study 
evaluates this very issue. In this study, 264 patients with a valid prescription from their 
prescriber were asked to answer various questions about their medication in a 
questionnaire. Patients responded to queries concerning side effects poorly. When the 
patients were asked “Which, side effects may occur,” 86.74 percent, nearly nine out of 
ten, patients answered incorrectly (Singh et al., 2013). Overall only thirty –five patients 
(13.26 %) knew about the side effects produced by their medication, and fifteen (5.68%) 
knew about how to recognize them (Singh et al., 2013). Healthcare providers find it 
important bridge the gap acknowledge concerning ADRs to avoid the skewed judgment 
of their treatment. Bandura’s social cognitive theory alludes that particularly various 
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experiences with ADRs are communicable. For example, if one individual perceives 
there medications as harmful without formal address by a healthcare provider can hinder 
medical literacy in population. These experiences can hypothetically be triggered by 
physiological feedback from ADRs.  This illiteracy about ADRs contributes to the poor 
judgement of self-efficacy, thus decrease in adherence.  
Healthcare providers can dissuade poor adherence among patients by being sensitive and 
responsive to individual vicarious experiences and physiological feedback with 
prescription medication adverse drug reactions. Adverse drug reactions serve as a 
formidable barrier against adherence. The study will assess the presence of the ADRs and 
their association with medication-taking behavior. The study postulates that patients who 
take prescribed medications who do not experience adverse drug reactions (ADR) have 
no difference in adherence rates than those commonly experience adverse drug reactions. 
The association between adherence and ADRs will enhance the understanding of the 
cognitive process of medication-taking behavior. 
Self-Monitoring Blood Pressure 
Patients who self-monitor their health conditions during treatment have been shown as a 
remedy to prevent poor adherence (World Health Organization Incorporated, 2003). The 
American Heart Association recommends that patients with high blood pressure (HBP) 
monitor their blood pressure at home to allow physicians optimize treatments for them 
(American Heart Association, 2014). Home blood pressure monitoring (HBPM) helps the 
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patient and physician know if the treatment being given is efficacious. Recording blood 
pressure daily provides a time-lapse picture of the selected treatment. This time-lapse 
picture helps doctors eliminate any possibility of false readings during clinical visits and 
observe any profound developments during the patient’s therapy (Brown & Bussell, 
2011).  
Medication adherence has been shown to develop with increase self-efficacy using a 
monitoring device. Self-efficacy can be improved by providing patients, particularly with 
chronic conditions such as hypertensive patients with electronic blood pressure cuffs 
(sphygmomanometers) to provide daily readings on blood pressure (American Heart 
Association, 2014). Professional and personal monitoring through clinical check-ups 
have increased adherence among patient. In 2013, Breaux-Shropshire and Brown 
conducted a cross-sectional study on the relationship between blood pressure and 
medication adherence among a population of municipal workers with access to 
healthcare. Breaux-Shropshire and Brown conducted a cross-sectional study with 149 
municipal employees. Approximately one-third of participants have been diagnosed with 
hypertension, and nearly half have some college education and take antihypertensive 
drugs to manage their HBP. The mean scores for medication adherence and medication 
adherence self-efficacy were of adequate range (5.97 to 6.07 and 3.44 to 3.57, 
respectively) (Breaux-Shopshire, Brown, Pryor, & Maples, 2013). Those patients with 
uncontrolled blood pressure scored a mean of higher (6.07) than those who had controlled 
blood pressure (5.97) (Breaux-Shopshire, Brown, Pryor, & Maples, 2013). Those were 
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homogenous with results for the medication adherence self-efficacy (Breaux-Shopshire, 
Brown, Pryor, & Maples, 2013). Significant findings in this study demonstrated a direct 
relationship between medication adherence and medication self-efficacy (r = 0.549, p < 
.001) (Breaux-Shopshire, Brown, Pryor, & Maples, 2013).  It should be noted that the 
participants in this study who participated in self-monitoring their chronic conditions 
improve their adherence and achieve optimal health outcomes (World Health 
Organization Incorporated, 2003). 
Nevertheless, parallels between self-monitoring equipment and individual approaches 
were not examined in a meta-analysis. Outcomes from the studies encompassed the meta-
analysis were not homogenous (Artinian et al., 2007). Nancy Artinian, a professor, and 
nurse with extensive clinical expertise, found a statistically significant reduction in 
systolic blood pressure among participants who self-monitored their blood pressure 
through a 12- month period (Artinian et al., 2007). The discrepancies between these 
studies may be attributed to differences between different aspects considered (Breaux-
Shopshire, Brown, Pryor, & Maples, 2013). The study measured community-based self-
monitoring, whereas this study observed home-based self-monitoring (Artinian et al., 
2007, Breaux-Shopshire, Brown, Pryor, & Maples, 2013). Medication adherence self-
efficacy did not predict blood pressure control due to the lack of variability with the study 
(Breaux-Shopshire, Brown, Pryor, & Maples, 2013). Nearly 48 percent of participants 
before the study had high medication adherence self-efficacy with 23 having medium 
medication adherence self-efficacy (Breaux-Shopshire, Brown, Pryor, & Maples, 2013).  
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Other factors that diminish variability in this study were the lack of questions on potential 
barriers to medication adherence (e.g. drug cost and adverse drug reactions) (Breaux-
Shopshire, Brown, Pryor, & Maples, 2013). Medication adherence and medication self-
efficacy have a positive direct relationship (Breaux-Shopshire, Brown, Pryor, & Maples, 
2013). Education and age were also positively correlated with medication self-efficacy 
(Breaux-Shopshire, Brown, Pryor, & Maples, 2013). This relationship shows medication 
adherence may be improved with self-regulation of these chronic conditions using 
medical devices that help with home monitoring (Breaux-Shopshire, Brown, Pryor, & 
Maples, 2013). 
Reviews and meta-analysis on basic elements of medication-taking behavior and self-
regulation reveal inconsistencies (Ebrahim, 1998).  A meta-analysis on adherence and 
self-regulation suggest that evidence for the effect of SMBP on lifestyle change and 
medication persistence is scarce, of poor quality, and proposes little clinically relevant 
benefit (Fletcher, Hartmann-Boyce, Hinton, & Mcmanus, 2015; Breaux-Shopshire, 
Brown, Pryor, & Maples, 2013). The investigators enquired if home blood pressure 
monitoring (HBPM) increases blood pressure control (Ogedegbe & Schoenthaler, 2006). 
A recent meta-analysis investigates a connection between medication adherence and 
personal blood pressure management.   
The Journal of Hypertension (Greenwich), investigators, conducted a systematic review 
to access the evidence from published randomized controlled trials (RCTs) on the 
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relationships between medication adherence concerning antihypertensive drugs and 
HBPM among patients (Ogedegbe & Schoenthaler, 2006). The review uncovered 11 
studies that focus on HBPM, self-reports, pill counts, pharmacy refills with medication 
adherence as an assessed outcome. In the analysis, 11 RCTs met predefined criteria 
reporting statistically significant improvements in medication-taking behavior. Nearly 
half of the RCTs in this review reported statistically significant positive correlations 
between medication adherence and HBPM interventions employed and the usual care. It 
should be noted that though the study was extensive, some RCTs may have been missed. 
Most responses that were reviewed contain small sample sizes that were less than 70 
patients. Only 82 percent RCTs allow the investigators to assess the independent effects 
of HBPM and adherence. Only three were conducted in primary care practices where 
most hypertensive patients receive care (Ogedegbe & Schoenthaler, 2006).  The findings 
in these studies have been shown to be consistent in other studies assessing self-efficacy 
and health outcomes. One study estimates self-efficacy among a sample of diabetic 
patients (Hernandez-Tejada, et al., 2012). The results displayed significant correlations 
with empowerment about medication adherence (r=0.17, p<0.003) and blood sugar 
testing (r=0.12, p=0.043) (Hernandez-Tejada, et al., 2012).  The collected data suggests 
that empowerment was related to better diabetes knowledge, medication adherence, and 
self-care behavior (Hernandez-Tejada, et al., 2012).  Overall, data from this review shows 
that effects of HBPM and patients’ medication-taking behavior remain mixed. With 54 
percent of the RCTs review reporting significant improvements in adherence to 
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interventions and usual care (Ogedegbe & Schoenthaler, 2006). Most patients who 
consume hypertensive medications are elderly and stricken by other supplementary 
chronic health conditions, such as hyperlipidemia, osteoarthritis, and diabetes mellitus 
type II. 
Medication adherence and self-monitoring are associated with one another according to 
Bandura’s SCT. Bandura elucidates in his theory that physiological feedback and self-
efficacy is linear. In the context of medication adherence, adherence can be established 
with the internal belief that the medication taken for their conditions is effective by 
monitoring the changes. This according to theory, monitoring can evoke an emotional 
arousal that is consistent manner thus increasing the magnitude of self-efficacy to 
complete the specific task of taking their medication as prescribed. Monitoring can 
reassure the patient that their medication is effective and help the individual gain a better 
understanding of the treatment and condition. The survey will ask participants questions 
to determine the relationship between self-monitoring blood pressure and adherence. The 
study hypothesizes that chronic disease patients who use medical monitoring devices that 
and measure vitals (blood sugar, blood pressure, etc.) for their illness become have 
greater adherence to the following prescribed drugs. Chronic disease patients who use 
medical monitoring devices that and measure vitals (blood sugar, blood pressure, etc.) for 





METHODS AND MATERIALS  
Participants 
The participants that will be part of this study will be retail pharmacy patients in the 
Edmond, Oklahoma. Each participant will receive a packet containing a consent form and 
a paper-based survey. Participants will be instructed to read informed consent document 
to concede to consent before concluding the paper survey. The informed consent and 
paper survey will take approximately 5 minutes to complete and will be provided in large 
font and at an eighth-grade reading comprehension level. Participants will not be asked 
for any identifying information, and a waiver of signed informed consent will be 
requested from the institutional review board at Oklahoma State University. Participants 
will be asked to return the completed packet, regardless of participation. Participants will 
receive five-dollar gift cards for completion of the survey.  
Instruments 
The study will be conducted through a demographic questionnaire along with one 
empirically tested questionnaire namely the Morisky Medication Adherence Scale survey 
(Morisky, Levine, Shapiro, Russell, & Smith, 1983). Other surveys will be synthesized 




The demographic questionnaire will ask questions about age, race, ethnicity, marital 
status, employment status, quality of insurance, and household income. The background 
information about the participant will be asked in the demographic questionnaire. The 
survey will help identify the type of population that will be used in the study and create 
subcategories based on demographic information. 
Morisky Medication Adherence Scale 
The Morisky Medication Adherence scale will be used to measure medication adherence, 
the individual’s self- report of compliance taking chronic illness drugs.  The core 
uniformity of Morisky Medication Adherence Scale was assessed using Cronbach’s alpha 
coefficients (Breaux-shropshire, Brown, Pryor, & Maples, 2013). This approach is 
commonly used to determine the homogeneity of an instrument (Polit & Beck, 2004).  
The Morisky Medication Adherence scale liability was reported to be at .74 (Darren & 
Mallery, 2003). Medication adherence self-efficacy, individuals’ confidence in adhering 
to routine drug rituals was measure by the revised Medication Adherence Self-Efficacy 
Scale (MASES-R).  
Self-Monitoring Using Medical Devices and Adherence 
The self-monitoring survey will be measured using a survey generated to ask questions 
concerning the use of medical devices and medical and medication adherence. This 
survey will ask participants to self-rate how they have felt about using their devices and 
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whether these devices aid in adherence with medication. The are no studies have 
demonstrated these survey questions a have strong reliability.  
Adverse Drugs Reactions and Adherence 
Adverse drugs reactions moiety of the survey will be measured by using a questionnaire 
developed by the researcher. The questionnaire is nine-item survey based on a Likert 
scale. This survey asks the participants to self-rate their experience with medications 
adverse drug reactions and healthcare professional supervision. No studies have 
confirmed strong reliability with this nascent test. 
Procedures 
Surveys will be distributed a local retail pharmacy. The paper survey will be circulated 
without exclusions. The study continues for three consecutive days and will be 
incentivized with five-dollar gifts from the pharmacy to allow for adequate sample size 
and statistical power for this study. The participants will be asked to complete all the 
surveys and return them to the retail pharmacy manager and personnel. All surveys that 
are fully completed and returned will be used for data collection.  
Statistical analysis 
Pearson's chi-squared test (X2) will be calculated to determine the cumulative probability 
of adverse drugs reactions, self-monitoring using devices, coverage, and demographics 
and how it relates to the medication adherence. The chi-squared test will be able to 
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FINDINGS AND DISCUSSION 
The survey elaborates using different groups of individuals who vary in mutable interest 
but shared other features in its methods to gauge any correlations between medication 
adherence, ADRs, and blood pressure monitoring using data collected for consumers an 
independent, family owned pharmacy serving a middle to high class socioeconomic 
population. The study was complete over three consecutive days during the pharmacy’s 
regular business hours. Overall thirty-six participants were recruited in the study. Small 
sample size may have weakened findings during data collection.  The frequencies for the 
demographics, blood pressure diagnosed patients, and medication adherence are 
Martial Status
SINGLE, NEVER MARRIED MARRIED OR DOMESTIC PARTNER
WIDOWED DIVORCED
SEPARATED
Figure 4 - Martial Status Frequency in study. 
31 
 
presented in figures (See Fig. 4-11). Frequencies for ethnicity and race were not included 









Figure 5 - Sex orientation frequency in study. 

















18-24 YEARS OLD 25-34 YEARS OLD 35-44 YEARS OLD
45-54 YEARS OLD 55-64 YEARS OLD 65-74 YEARS OLD
75 YEARS OR OLDER
Figure 7 - The age frequency in the study. 





Diagnosed w/ Hypertension Not Diagnosed
Insurance
Insurance No Insurance
Figure 9 - The frequency of individuals that have been diagnosed with hypertension by a certified 
healthcare provider. 




When preforming the statistical analysis, the chi-square statistical method was chosen. 
This method was chosen due the applicability and common use with cross-sectional 
correlation studies. Some individuals did not answer all questions, and as a result were 
jettison from the study. The sample was homogenous, not much diversity among 
participants. The participants scored an average of 71.39 on the Morisky Medication 
Adherence Scale. If participants scored above 70%, they were considered adherent. 
Approximately 50% of the participants in the sample were adherent to their prescribed 
medications. Conferring to chi-square statistics, individuals who consumed medication 
with insurance displayed no difference in adherence rates in without insurance (p>0.05, w 
= 0.87).  Furthermore, data reveal no significant differences between sources of health 
coverage and adherence rates (p>0.05, V=0.18). The study failed to reject the null 
hypothesis for adherence and adverse drug reactions. In the sample we observed no 
Household Income (before taxes)
29K or less 30k-49K 50k-79K 80K-Above N/A
Figure 11 - Household Income, before taxes, frequency for the study. 
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difference in adherence rates among individuals who have experienced adverse drug 
reactions than those who have not experienced adverse drug reactions with prescribed 
medication (p>0.05, w=0.67).  Due to lack of data; the study failed to find any 
association between clinician-patient relationship, ADR, and medication adherence; 
concomitantly. These results were analogous to findings for participants evaluated on 
blood pressure monitoring or charting skills. The results disclose that there was no 
difference in adherence rates under individuals who monitor their blood than individuals 
who do not (p>0.05, V=0.18).  When observing and comparing demographics, no 
difference was present within the sample in adherence rates. There was no correlation 
between adherence and age (p>0.05, V = 1.13), marital status (p>0.05, V= 0.26), current 
annual household (before taxes) (p>0.05, V= 0.94), and sex (p>0.05, w=0.49). A larger 
sample size is needed for more statistical power to accurately represent the population of 
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Self-Monitoring Blood Pressure and Adherence
Adherent Non-adherent
Figure 13 - The graph reveals the association between self-monitoring blood pressure and medication adherence. 






The study’s incorporation of the Morisky Mediation Adherence Scale scores did reflect 
adherence percentages (approximately 50%) analogous to findings in the literature 
(World Health Organization Incorporated, 2003; Brown & Bussell, 2011). The scales 
used to measure self-monitoring, and charting of blood pressure and adverse drug 
reactions require rebuilding to obtain additional data and accurate assessment. The weak 
survey areas in the organization of questions and navigational and time-saving techniques 
designed for the participants taking the survey. The weak areas may contribute to the low 
yield of answers in particular sections of the survey.  
During the three consecutive days of data collection, some surveys were not completed. 
Participants were asked to complete the survey as directed under the supervision of the 
principal investigator. In the study, only four participants were not adequately supervised, 
and surveys were not properly reviewed in the section composed of the Morisky 
Medication Adherence assessment. Some individuals turned in surveys to the pharmacy 
and skipped individual questions in this section.  
The survey contains two questions in the first section (SECTION 1- Adverse Drug 
Reactions) related to the clinician-patient relationship and adverse drug reactions 
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hypothesis. The questions are followed-up by questions first concerning their experience 
with adverse drug reactions. Often participants reported not experiencing adverse drug 
reaction with their prescribed medication. The subjects were instructed to proceed to the 
next section in the survey. This design in the survey left the questions of concern 
answered only by a few participants. Data collected, from the few participants who 
answer these questions, did not suffice for utilization in concluding. 
During data collection and observations, the participants seem to have struggled in 
navigating through the survey. During reviewing and scoring of the survey, often abstract 
markings were made and written saltatory action cues were ignored. Participants move to 
each question, skipping questions and sections of the study. Inquiries in the investigation 
left some participants vexed, due to limited choices that did not necessarily resonate as 
their answer. The questions should be reorganized in a manner that has a gradual 
transition from one question to another. Also, improving the practical mechanisms of the 
survey should include focusing on developing quick cognitive appraisals of each 
question. Reconstructing questions to be more recognizable may incur a more accurate 
and lucid response from participants.  For example, “When taking medication do you 
experience the following: side effects…issues with refilling prescriptions…issues with 
talking to your health care provider?” The participant would review the following 
selections and check all that apply, opposed to asking each question individually. 
Improving functional devices such as proper organization and phrasing of the questions 







Medication adherence is influenced by a multitude of factors, illustrating the complex 
and individual character behind this behavior. Albert Bandura’s Social Cognitive 
Theory’s construct of self-efficacy is a valid framework for understanding the complex 
and personal nature of medication adherence. Discerning the determinants of adherence 
can aid health care professionals, enhance care for their patients, and placate pecuniary 
expenses in healthcare enterprise. The study of medication adherence is an emerging 
subject of concern in the health industry. Stakeholders are beginning to understand some 
of the increasing economic burdens that exist in this sector. Furthermore, both 
stakeholders and healthcare professionals, with understanding the implications of the 
rising financial load, cannot optimize pharmacotherapeutic care solely through the 
benefit-risk profiles of medication, but from adherence of the patient receiving the drug. 
The focus of the study was to discover correlations between three determinants: adverse 
drug reactions, self-monitoring of blood pressure, health care professional 
encouragement, and adherence. The study reveals adherence is not linear to the selected 
determinants or demographics. This suggest that other factors may play a larger role in 
adherent behavior. Nevertheless, given the small sample size and limitations of the study, 
a larger sample size is required to accurately reflect the population of consumers in 
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family-owned, independent pharmacies in Oklahoma.  For future research, objective (e.g. 
pill counting and pharmacy refill records), biochemical (e.g. serum drug levels), and 
further subjective measurements (e.g. family members observance via survey) must be 
used and equated to obtain an accurate and precise assessment of core determinants of 
medication adherence. Incorporation of all three measurements of adherence give 
investigators a more fluid and functional standpoint in gaining a better understanding of 
medication adherence. Research in the future should engender approaches to reveal an 
association between medication-taking behavior and health outcomes. 
A systematic review discloses that conducted interventions for home blood pressure 
monitoring (HBPM) in primary care settings were not effective compared with those that 
occurred in hospital-based clinics or nonclinical settings (Ogedegbe & Schoenthaler, 
2006). The data on the effects of HBPM on patients' medication-taking behavior were 
shown to be mixed. Future studies should investigate the independent effects of HBPM in 
primary care practices where many hypertensive patients receive their care (Ogedegbe & 
Schoenthaler, 2006). These studies address the issue by advising future studies to be 
conducted in primary care setting and reveal an association between optimal health 
outcomes and adherence.  
The study influenced by limitations to recruiting individuals from a pharmacy. 
Alternative settings in future studies should be explored. Pharmacy is limited to 
individuals who are adherent to a degree. I hypothesize that patients in a pharmacy are 
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more likely to be more adherent to medical advice than patients in a clinic-based or 
community-based sample. Studies to validate the assumption will support future studies.  
Alternative theoretical frameworks are essential in gaining clarity to the complexity of 
the cognitive process behind medication adherence. One applicable theory for the 
elucidation of medication taking behavior is the Theory of (reasoned) Planned Behavior. 
The Theory of Reasoned Behavior is model for behavioral intentions. This model is 
congruenent to evidence of behavioral intentions given the determinants and the intricacy 
behind the medication-taking behavior. This theory has been attenuating by Icek Ajzen’s 
extended model, the theory of planned behavior, which attempts to describe behavior and 
attitude using the construct of perceived behavioral control. (Ajzen, 1991) This model of 
the theory of planned behavior explains how an individual’s behavior is directly related 
to belief. Whereas individuals can “control” their behaviors. There are three fundamental 
constructs of this model that explain and describe the apparent behaviors and ability of 
own to exert “self-control” behavioral intentions influence by one’s attitude or self-
evaluation of behavior (what I think), subjective norm (what others think), and perceived 
control behavior (what I think and what “should” to do, considering the subjective norms 
and beliefs and self-behavior evaluation) (Ajzen, 1991). The theoretical model of self-
efficacy explains how specific determinants may influence individual intentions.  The 
theory of planned behavior possesses a construct, perceived control behavior. This 
construct is derived from Albert Bandura’s theory of efficacy (Ajzen, 1991).  This 
theoretical framework may dispel influencing factors behavior intentions, and cognitive 
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process oppose that lead to medication adherence, optimal health outcomes, and 
eventually a better quality of life. 
 
Poor medication adherence is complex to combat.  Furthermore, poor adherence has 
deleterious implications for patients who are not adherent to their prescribed medications. 
Healthcare professionals and stakeholders are becoming more aware of medication-
taking patterns of patients and interventions to combat poor adherence are in 
development. Many responses are using a more technological approach to decreasing the 
perils of medication non-adherence. Electronic wireless devices such as pill bottles and 
trackable pills may aid in mollify pill-taking regime, but experts express that it not a cure 
for poor medication adherence among patients.  Dr. Niteesh Choudhry, an internist at 
Harvard Medical School, conduct a study to get a clearer understanding of these devices 
and the association with medication adherence (Silverman, 2017). Dr. Choudhry 
conducted the investigation to assess the efficacy of the smart bottle; required synthesize 
a device of his own. The device included a “Timer cap” to aid as a reminder to take daily 
doses of the medication.  Dr. Choudhry also found to differences in adherence among 
those who use conventional weekly pill boxes (Silverman, 2017). Many critics point out 




Other technologies have been utilized to improve medication adherence among patients. 
The Food and Drug Administrations (FDA) regulators have approved the first pill that 
can be digitally tracked through the body. The drug Abilify® MyCite is an aripiprazole 
tablet. Aripiprazole is a drug used for treating schizophrenia and manic episodes. The pill 
is equipped with an ingested sensor embedded inside the tablets that indicate that 
medication has consumed. Schizophrenic patients where a patch that transmits data to 
their smartphone (Abderrahman, 2017).  Many healthcare professionals find this 
information useful. However, many agree that the information in the wrong hands may 
become more harmful than beneficial for patients and healthcare professionals. 
 
 
The problem with medication adherence is the complex and individual nature of the 
behavior. These two characteristics make medication adherence empirically 
multifactorial.  Patients are non-adherent to medications for a multitude of reasons, many 
amendable but influenced by the environment. Thus, practical interventions on 
medication adherence should be specific for a patients’ disease or condition, treatment, 
and other determinants that effect solely those patients (Ogedegbe & Schoenthaler, 
2006).  Smart bottles placate common medication-related behavior issues that often come 
to surface, such as forgetfulness (World Health Organization Incorporated, 2003). 
Advances in technology may bring healthcare professionals to closer to slaking economic 
45 
 
burden and placating adverse clinical outcomes with patients who practice poor 
medication adherence. Nevertheless, technological advances used to improve adherence 
are only asymptotic, but practical and economically necessary in battling the complexities 
behind the medication-taking behavior, bringing heathcare professionals ever so close to 
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